Table 1 Multispecific T cell engagers approved, in review or in late stage clinical trials, as of July 2023
From: Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Drug name | Format | Specificity | Indication | Clinical trial | Phase | Sponsor |
|---|---|---|---|---|---|---|
Blinatumomab | BiTE | CD19/CD3 | ALL | NCT02013167 | Marketed 2014 | Amgen |
Mosunetuzumab (RG7828, CD20-TDB) | Hz IgG1-based, Fc -silent, KIH | CD20/CD3 | FL | NCT02500407 | Marketed 2022 | Genentech-Roche |
Epcoritamab (GEN3013) | Hz/hu IgG1-based Duobody | CD20/CD3 | DLBCL | NCT03625037 | Marketed 2023 | Genmab-Abbvie |
Glofitamab (RO7082859, RG6026) | Hz IgG1-based 2 + 1 CrossMab | CD20/CD3 | DLBCL | NCT03075696 | Marketed 2023 | Roche |
Odronextamab (REGN1979) | Hu IgG4-based, VelociBi | CD20/CD3 | NHL | NCT03888105 | 2 (potentially pivotal) | Regeneron |
Teclistamab (JNJ 7957) | Hz IgG4 Duobody | BCMA/CD3 | MM | NCT04557098 | Marketed 2022 | Janssen |
Elranatamab (PF-06863135) | Hz IgG2, hinge-mutation | BCMA/CD3 | MM | NCT05020236 | In review | Pfizer |
Linvoseltamab (REGN5458) | IgG4 VelociBi | BCMA/CD3 | MM | NCT03761108 | 2 (potentially pivotal) | Regeneron |
Talquetamab (JNJ 7564) | Hz IgG4 Duobody | GPRC5D/CD3 | MM | NCT04634552 | In review | Janssen |